Starting out, Aldevron founders Michael Chambers and John Ballantyne had one thing in common besides being fascinated with biotechnology and its applications in health care. They are both graduates of North Dakota State University (NDSU) in Fargo.
CRISPR/Cas9 is a vital part of our research at the University of Minnesota and the Cas9 recombinant protein, used at high concentration, has allowed for highly efficient modification of T-cells.
By introducing a Cas9 nuclease guide RNA complex (RNP), we target a specific spot in the genome, where the nuclease cuts the DNA. The DNA break is repaired in one of two ways: homologous recombination, which is high-fidelity, or non-homologous endjoining (NHEJ), which is more error-prone.
